Narrative review / 2007
Only about one-third to one-half of people can convert the soy isoflavone daidzein into equol via intestinal microflora.
Soy isoflavones are linked to lower rates of cardiovascular disease, osteoporosis, and some cancers. Clinical efficacy may rely on biotransforming daidzein into equol, a metabolite with greater estrogen receptor affinity, antiandrogenic properties, and superior antioxidant activity. Only about one-third to one-half of the population can produce equol, likely due to interindividual variations in gut microflora, though specific bacterial species responsible remain to be identified.
Shows an association, not proof of cause and effect.
- Study type
- Narrative review
- Who was studied
- Human population consuming soy isoflavones
- What was measured
- Equol production from daidzein and related health implications
THE PAPER
Metabolism of dietary soy isoflavones to equol by human intestinal microflora--implications for health.
Yuan JP, Wang JH, Liu X. Mol Nutr Food Res, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.